News Room

The sluggish rollout of COVID-19 vaccines across the United States highlights the challenges of a decentralized distribution plan that relies on states and localities to handle the complicated last-mile logistics of getting shots into people's arms, reported The Wall Street Journal on Monday. More than 22 million doses had been distributed to states and other jurisdictions as of Friday, according to the Centers for Disease Control and Prevention (CDC), while 6.7 million people had received their first shot by that point. The figures were short of the U.S. goal of 20 million vaccinations by the end of 2020, and communities and states were still reporting bottlenecks this month as they managed their inoculation programs, said the Journal.

The output from Operation Warp Speed is struggling to get its footing. The billions of dollars invested focused primarily on developing a safe and effective vaccine as quickly as possible. Equally needed was how to effectively traverse all the links in the supply chain, particularly the last mile, to transform those vaccines into vaccinations. As a result, millions of doses of vaccines sit on shelves while willing recipients anxiously await their turn to be immunized. What went wrong and what can be done today to make this right?  

For many of us, one of the upsides of 2020 was being freed from the grind of the daily commute. For the 40% of the workforce able to “telecommute”, COVID-19 social distancing measures saved us an average of about an hour a day – and much more for those of us living in the outer suburbs of cities. Studies show the morning commute is the least favourite part of the day, and the commute home the third-least favourite (working is the second-least favourite). Congestion, crowding and unpredictability increase stress and dissatisfaction. The longer it takes, and the more we have to do in the company of others, the more we dislike it.

Like certain celebrities, the “vaccine” does not need a first name or modifier. Data from both Pfizer and Moderna have shown their COVID-19 vaccines to be nearly 95% effective in preventing disease in people who received two doses, thus earning a green light from the Food and Drug Administration. Other vaccines in clinical trials also are showing promising results. Although vaccine doses have been distributed to all states, limited quantities will force states to prioritize those who should get the first doses.